Home / Market News / $ADXN

$ADXN news and market catalysts

The 7 most recent market catalysts affecting $ADXN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 2 high impact 4 bullish 2 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Bullish Impact 65
Addex Therapeutics Spin-Out Neurosterix Closes $105 Million Series B Financing
Addex Therapeutics reported that its spin-out company, Neurosterix, successfully closed a $105 million Series B financing round. This event is significant because it provides subst…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Addex Therapeutics Increases Issued Share Capital to Create Treasury Shares
Addex Therapeutics has increased its total issued share capital by issuing 93 million new shares to its 100% owned subsidiary. This move is a technical financial maneuver to create…
Oct 8, 2026 Corporate Catalyst Neutral Impact 75
Addex Spin-Out Neurosterix Wraps Phase 1 Of NTX-253 With Single And Multiple Ascending Dose Studies Providing Safety And Pharmacokinetic Data, Plans Phase 2 Schizophrenia Development
This headline signals a significant de-risking event for NTX-253, a potential treatment for schizophrenia. Successful Phase 1 completion, particularly with good safety and pharmaco…
Sep 28, 2026 Corporate Catalyst Bearish Impact 92
Addex Therapeutics Q2 EPS $(1.52) Up From $(2.90) YoY, Sales $12.650K Down From $44.031K YoY
Addex Therapeutics (ADXN) disclosed its Q2 earnings, revealing a substantial 71.27% year-over-year decrease in sales, dropping from $44.031 thousand to $12.650 thousand. While the …
Sep 28, 2026 Corporate Catalyst Bearish Impact 95
CORRECTION: Addex Therapeutics Q2 EPADS $(2.16) Up From $(2.90) YoY, Sales $12.650K Down From $44.031K YoY
Addex Therapeutics (ADXN) disclosed its Q2 earnings, revealing a dramatic 71.27% year-over-year decrease in sales, falling from $44.031 thousand to $12.650 thousand. While the comp…
Sep 25, 2026 Corporate Catalyst Bullish Impact 75
Addex Therapeutics shares are trading higher after the company announced it regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior UK.
This headline is a significant corporate catalyst for Addex Therapeutics, as regaining full global rights to GABAB positive allosteric modulator assets provides them with complete …
Aug 26, 2026 Corporate Catalyst Bullish Impact 65
Addex Therapeutics Raises $2.8M Gross Proceeds Through ATM Sale Of 437,869 ADSs, Extends Cash Runway To Q4 2027
This headline indicates a common strategy for small-cap biotech companies: raising capital through an At-The-Market (ATM) offering. While the $2.8 million is a relatively small amo…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.